Abstract
Irreversible electroporation (IRE) is a new non-thermal ablation modality that uses short pulses of DC electric current to create irreversible pores in the cell membrane thus causing cell death. This method has been shown by Rubinsky et al. to have significant advantages in ablating prostatic tissue, such as rapid lesion creation, rapid lesion resolution, sparing of structures such as vessels, nerves and urethra, and uniform destruction throughout the IRE lesion (1). The underlying principles are well covered in other chapters in this book. This discussion will deal with the first human applications of IRE and whether its theoretical promises of improved clinical outcomes, have been delivered. For a number of reasons, including the ability to carry out extensive post operative biopsies to confirm the adequate ablation of cancer, the first human experience was carried out in the prostate.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Rubinsky, B., Onik, G., Mikus, P.: Irreversible electroporation: a new ablation modality–clinical implications. Technol. Cancer Res. Treat. 6(1), 37–48 (2007)
Onik, G., Narayan, P., Vaughan, D., et al.: Focal nerve sparing cryoablation for the treatment of primary prostate cancer: A new approach to preserving potency. Urology 60(1), 109–114 (2002)
Onik, G., Vaughan, D., Lotenfoe, R., Dineen, M., Brady, J.: Male lumpectomy: focal therapy for prostate cancer using cryoablation. Urology 70(suppl. 6), 16–21 (2007)
Bahn, D.K., Silverman, P., Lee, F., Badalament, R., Bahn, E.D., Rewcastle, J.C.: Focal prostate cryoablation: initial results show cancer control and potency preservation. J. Endourol. 20(9), 688–692 (2006)
Lambert, E.H., Bolte, K., Masson, P., Katz, A.E.: Focal cryosurgery: encouraging health outcomes for uni-focal prostate cancer. Urology 69(6), 1117–1120 (2007)
Bahn, D.K., Lee, F., Bandalament, R., et al.: 7-year outcomes in the primary treatment of prostate cancer. Urology 60(suppl. 1, 2), 3–11 (2002)
Bostwick, D.G., Waters, D.J., Farley, E.R., Meiers, I., Rukstalis, D., Cavanaugh, W.A., Ragde, H., Dineen, M.K., Bahn, D., Scionti, S., Babian, R., Ellis, D.S., Rewcastle, J.C., Burke, H.B., Andriole, G.L., Onik, G., Barqawi, A.E., Maksem, J., Barzell, W.E.: Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida (February 24, 2006); Urology 70(suppl. 6), 42–44 (December 2007)
Santiago, R.J., Wu, L., Harris, E., Fox, K., Schultz, D., Glick, J., Solin, L.J.: Fifteen-year results of breast-conserving surgery and definitive irradiation for Stage I and II breast carcinoma: the University of Pennsylvania experience. Int. J. Radiat. Oncol. Biol. Phys. 58(1), 233–240 (2004)
Messing, E.M., Thompson, I.: Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy. Urol. Clin. North Am. 30(4), 687–702 (2003)
Djvan, B., Susani, M., Bursa, B., et al.: Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Techniques in Urology 5(3), 139–142 (1999)
Villars, A., McNeal, J.E., Freiha, F.S., et al.: Multiple cancers in the prostate. Morphological features of clinically recognized vs. incidental tumors. Urology 60(2A), 19–25 (2002)
Noguchi, M., Stamey, T.A., McNeal, J.E., et al.: Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: Lack of significance of secondary tumors. J. Uril. 170(2pt), 459–463 (2003)
Rukstalis, D.B., Goldknopf, J.L., Crowley, E.M., et al.: Prostate cryoablation: A scientific rationale for future modifications. Urology 60(2A), 19–25 (2002)
Crawford, E.D., Wilson, S.S., Torkko, K.C., et al.: Clinical staging of prostate cancer: A computer-simulated study of transperineal prostate biopsy. BJU Int. 96(7), 999–1004 (2005)
Gary Onik, M.D., Winston Barzell, M.D.: Transperineal 3D Mapping Biopsy of the Prostate: An Essential Tool in Selecting Patients for Focal Prostate Cancer Therapy. Urologic Oncology: Seminars and Original Investigations (in Press)
Barzell, W.E., Melamed, M.R.: Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate–a 4-year experience. Urology 70(suppl. 6), 27–35 (2007)
Health Care Financing Administration. Medicare Coverage Policy: Decisions. Bagley GP. Cryosurgery ablation of the prostate (#CAG-00031), http://www.hcfa.gov/coverage/8b3-f1.htm (accessed November 7, 2001)
Donnelly, B.J., Saliken, J.C., Brasher, P., et al.: Randomized controlled trial comparing external beam radiation and cryoablation in localized prostate cancer. In: Proceedings of the American Urological Association of 2007 (2007), Abstract #1141
Eggener, S.E., Scardino, P.T., Carroll, P.R., Zelefsky, M.J., Sartor, O., Hricak, H., Wheeler, T.M., Fine, S.W., Trachtenberg, J., Rubin, M.A., Ohori, M., Kuroiwa, K., Rossignol, M., Abenhaim, L.: International Task Force on Prostate Cancer and the Focal Lesion Paradigm. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J. Urol. 178(6), 2260–2267 (2007) (Epub October 15, 2007)
Ahmed, H.U., Pendse, D., Illing, R., Allen, C., van der Meulen, J.H., Emberton, M.: Will focal therapy become a standard of care for men with localized prostate cancer? Nat. Clin. Pract. Oncol. 4(11), 632–642 (2007)
Mouraviev, V., Mayes, J.M., Sun, L., Madden, J.F., Moul, J.W., Polascik, T.J.: Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 110(4), 906–910 (2007)
Neumann, E., Schaefer-Ridder, M., Wang, Y., Hofschneider, P.H., et al.: Gene transfer into mouse lyoma cells by electroporation in high electric fields. J. EMBO 1, 841–845 (1982)
Mir, L.M., Belehradek, M., Domenge, C., Luboniski, B., Orlowski, S., Belehradek, J., Schwaab, B., Luboniski, B., Paoletti, C.: Electrochemotherapy, a novel antitumor treatment: first clinical trial. C. R. Acad. Sci. Ser. III 313, 613–618 (1991)
Davalos, R.V., Mir, L.M., Rubinsky, B.: Tissue ablation with irreversible electroporation. Annals of Biomedical Engineering 33(2), 223–231 (2005)
Onik, G., Mikus, P., Rubinsky, B.: Irreversible electroporation: implications for prostate ablation. Technol. Cancer Res. Treat. 6(4), 295–300 (2007)
Miller, L., Leor, J., Rubinsky, B.: Cancer cells ablation with irreversible electroporation. Technology in Cancer Research and Treatment 4(6), 1–6 (2005)
Ellis, D., Jones, J., Pisters, L., et al.: Subtotal/Partial gland prostate cryoablation: Results of 341 patients from multiple centers tracked with the cold registry. Presented AUA 2008, Orlando FL (2008), Abstract Number:08-AB-95484-AUA
Lavee, J., Onik, G., Mikus, P., Rubinsky, B.: A novel non-thermal energy source for surgical epicardial atrial ablation: irreversible electroporation. Heart Surg. Forum 10(2), E162–E167 (2007)
Donnelly, B.J., Salikan, J.C., Ernst, D.S., et al.: Prospective trial of cryosurgical ablation of the prostate: Five year results. Urology 60(4), 645 (2002)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Onik, G., Rubinsky, B. (2010). Irreversible Electroporation: First Patient Experience Focal Therapy of Prostate Cancer. In: Rubinsky, B. (eds) Irreversible Electroporation. Series in Biomedical Engineering. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-05420-4_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-05420-4_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-05419-8
Online ISBN: 978-3-642-05420-4
eBook Packages: EngineeringEngineering (R0)